secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001161697-21-000521
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q3 net loss $1.1M; revenue $6.0M, 9% sequential growth
-------------------------------------------------------------------

- Net revenue $6.0M, 9% sequential growth; adjusted net revenue up 9% YoY excluding prior year inventory stocking.
- Net loss $1.1M ($0.02 per share) vs net income $0.2M ($0.01) in Q3 2020.
- Gross margin 57.9%, down from 64.8% due to manufacturing transition delays and scrap reserve.
- Received FDA 510(k) clearance for Hizentra 20ml prefilled syringe with Freedom Edge system.
- Three leadership hires and strategic plan update scheduled for December 2, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169721000521/0001161697-21-000521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169721000521/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-21-000521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer